LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
press release announcing preliminary revenue for fourth quarter
2016 and guidance for 2017 revenue. A copy of the press release
is furnished herewith as Exhibit 99.1.
(Investor Presentation) to investors discussing, among other
topics, an overview of the Companys business and growth strategy.
The presentation will be at the 35th Annual J.P. Morgan
Healthcare Conference in San Francisco, CA and will begin at 8:00
a.m. Pacific time (11:00 a.m. Eastern time). A copy of the
Investor Presentation, which is available at www.luminexcorp.com,
is being furnished as Exhibit 99.2 to this Form 8-K and is
incorporated herein by reference.
Form 8-K, including the Press Release attached as Exhibit 99.1
and Investor Presentation attached as Exhibit 99.2, is being
furnished and shall not be deemed filed for purposes of Section
18 of the Securities and Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to liabilities under that
section, nor shall it be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as otherwise stated in such filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release issued by Luminex Corporation dated
January 9, 2017. |
|
|
99.2
|
Investor Presentation
|
About LUMINEX CORPORATION (NASDAQ:LMNX)
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease. LUMINEX CORPORATION (NASDAQ:LMNX) Recent Trading Information
LUMINEX CORPORATION (NASDAQ:LMNX) closed its last trading session up +0.31 at 20.67 with 110,288 shares trading hands.
